106 related articles for article (PubMed ID: 34190333)
1. KRAS mutation identified in a patient with melorheostosis and extended lymphangiomatosis treated with sirolimus and trametinib.
Lacasta-Plasin C; Martinez-Glez V; Rodriguez-Laguna L; Cervantes-Pardo A; Martinez-Menchon T; Sanchez-Jimenez R; Campos-Dominguez M
Clin Genet; 2021 Oct; 100(4):484-485. PubMed ID: 34190333
[TBL] [Abstract][Full Text] [Related]
2. Melorheostosis and Osteopoikilosis: A Review of Clinical Features and Pathogenesis.
Wordsworth P; Chan M
Calcif Tissue Int; 2019 May; 104(5):530-543. PubMed ID: 30989250
[TBL] [Abstract][Full Text] [Related]
3. Melorheostosis: Exome sequencing of an associated dermatosis implicates postzygotic mosaicism of mutated KRAS.
Whyte MP; Griffith M; Trani L; Mumm S; Gottesman GS; McAlister WH; Krysiak K; Lesurf R; Skidmore ZL; Campbell KM; Rosman IS; Bayliss S; Bijanki VN; Nenninger A; Van Tine BA; Griffith OL; Mardis ER
Bone; 2017 Aug; 101():145-155. PubMed ID: 28434888
[TBL] [Abstract][Full Text] [Related]
4. Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure.
Barbie DA; Spira A; Kelly K; Humeniuk R; Kawashima J; Kong S; Koczywas M
Clin Lung Cancer; 2018 Nov; 19(6):e853-e859. PubMed ID: 30087028
[TBL] [Abstract][Full Text] [Related]
5. Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells.
Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Niki T; Takahashi H; Sakuma Y
Biochem Biophys Res Commun; 2018 Jun; 501(1):253-258. PubMed ID: 29727601
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
Huijberts SCFA; van Geel RMJM; van Brummelen EMJ; Opdam FL; Marchetti S; Steeghs N; Pulleman S; Thijssen B; Rosing H; Monkhorst K; Huitema ADR; Beijnen JH; Bernards R; Schellens JHM
Cancer Chemother Pharmacol; 2020 May; 85(5):917-930. PubMed ID: 32274564
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
[TBL] [Abstract][Full Text] [Related]
8. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
[No Abstract] [Full Text] [Related]
9. Trametinib and Hydroxychloroquine (HCQ) Combination Treatment in KRAS-Mutated Advanced Pancreatic Adenocarcinoma: Detailed Description of Two Cases.
Xavier CB; Marchetti KR; Castria TB; Jardim DLF; Fernandes GS
J Gastrointest Cancer; 2021 Mar; 52(1):374-380. PubMed ID: 33225411
[TBL] [Abstract][Full Text] [Related]
10. Novel Somatic Mutation in LEMD3 Splice Site Results in Buschke-Ollendorff Syndrome with Polyostotic Melorheostosis and Osteopoikilosis.
Gutierrez D; Cooper KD; Mitchell AL; Cohn HI
Pediatr Dermatol; 2015; 32(5):e219-20. PubMed ID: 26135202
[TBL] [Abstract][Full Text] [Related]
11. Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment.
Piha-Paul SA; Hong DS; Kurzrock R
J Clin Oncol; 2011 Apr; 29(12):e333-5. PubMed ID: 21263090
[No Abstract] [Full Text] [Related]
12. Trametinib and Dabrafenib in histiocytic sarcoma transdifferentiated from chronic lymphocytic leukemia with a K-RAS and a unique BRAF mutation.
Rassidakis GZ; Stromberg O; Xagoraris I; Jatta K; Sonnevi K
Ann Hematol; 2020 Mar; 99(3):649-651. PubMed ID: 32009180
[No Abstract] [Full Text] [Related]
13. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers.
Dai X; Xia H; Zhou S; Tang Q; Bi F
Cancer Lett; 2019 Feb; 442():202-212. PubMed ID: 30429107
[TBL] [Abstract][Full Text] [Related]
15. Novel and recurrent germline LEMD3 mutations causing Buschke-Ollendorff syndrome and osteopoikilosis but not isolated melorheostosis.
Zhang Y; Castori M; Ferranti G; Paradisi M; Wordsworth BP
Clin Genet; 2009 Jun; 75(6):556-61. PubMed ID: 19438932
[TBL] [Abstract][Full Text] [Related]
16. Low‑dose trametinib and Bcl‑xL antagonist have a specific antitumor effect in KRAS‑mutated colorectal cancer cells.
Koyama M; Kitazawa M; Nakamura S; Matsumura T; Miyazaki S; Miyagawa Y; Muranaka F; Tokumaru S; Okumura M; Yamamoto Y; Ehara T; Hondo N; Takahata S; Takeoka M; Miyagawa SI; Soejima Y
Int J Oncol; 2020 Nov; 57(5):1179-1191. PubMed ID: 32901840
[TBL] [Abstract][Full Text] [Related]
17. Immunogenic chemotherapy effectively inhibits KRAS-Driven lung cancer.
Wang D; Cong J; Fu B; Zheng X; Sun R; Tian Z; Wei H
Cancer Lett; 2020 Nov; 492():31-43. PubMed ID: 32758617
[TBL] [Abstract][Full Text] [Related]
18. Germline LEMD3 mutations are rare in sporadic patients with isolated melorheostosis.
Hellemans J; Debeer P; Wright M; Janecke A; Kjaer KW; Verdonk PC; Savarirayan R; Basel L; Moss C; Roth J; David A; De Paepe A; Coucke P; Mortier GR
Hum Mutat; 2006 Mar; 27(3):290. PubMed ID: 16470551
[TBL] [Abstract][Full Text] [Related]
19. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
Borthakur G; Popplewell L; Boyiadzis M; Foran J; Platzbecker U; Vey N; Walter RB; Olin R; Raza A; Giagounidis A; Al-Kali A; Jabbour E; Kadia T; Garcia-Manero G; Bauman JW; Wu Y; Liu Y; Schramek D; Cox DS; Wissel P; Kantarjian H
Cancer; 2016 Jun; 122(12):1871-9. PubMed ID: 26990290
[TBL] [Abstract][Full Text] [Related]
20. KRAS-driven model of Gorham-Stout disease effectively treated with trametinib.
Homayun-Sepehr N; McCarter AL; Helaers R; Galant C; Boon LM; Brouillard P; Vikkula M; Dellinger MT
JCI Insight; 2021 Aug; 6(15):. PubMed ID: 34156985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
